Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect of Meal Frequency on Insulin Resistance, Insulin Secretion, and Hepatic Fat Content in Subjects With Type 2 Diabetes
Aims and priorities of the project The purpose of this study is to
1. test the effect of frequency of meals (six vs. two meals daily with the same daily
caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and
hepatic fat content.
2. characterize some of the mechanisms of action of different frequencies of meals (amount
of visceral fat, hepatic fat content, serum concentrations of adipokines, gut hormones,
oxidation stress markers).
3. test the ability of the participants to maintain hypocaloric diet on both regimens when
educated and left to prepare their meals alone in comparison with those for whom all
meals during the study will be provided.
It will be a randomized, crossover study, where 50 individuals with type 2 diabetes will
change in a random order two regimens: six, and two meals a day. Each testing period will
take three months.
Glucose and lipid metabolism and its regulation will be thoroughly tested at start, and
after each 3-months-period (meal test, hyperinsulinemic isoglycemic clamp, indirect
calorimetry, MRI scan of the liver, DXA scan, serum concentration determination of selected
adipokines, gut hormones, and oxidation stress markers).
Hypothesis The investigators hypothesize that low plasma insulin levels (as achieved by
periods of fasting) will reduce insulin resistance and hepatic lipid content. In contrast,
frequent meals (and consequent higher plasma levels of insulin) will predispose to
non-alcoholic fatty liver disease and insulin resistance. The investigators further
hypothesize that the participants will increase their caloric intake with increased meal
frequency (in spite of thorough education) when left to prepare their meals in comparison
with those for whom all meals will be provided.
Aims and priorities of the project The purpose of this study is to
1. test the effect of frequency of meals (six vs. two meals daily with the same daily
caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and
hepatic fat content.
2. characterize some of the mechanisms of action of different frequencies of meals (amount
of visceral fat, hepatic fat content, serum concentrations of adipokines, gut hormones,
oxidation stress markers).
3. test the ability of the participants to maintain hypocaloric diet on both regimens when
educated and left to prepare their meals alone in comparison with those for whom all
meals during the study will be provided.
It will be a randomized, crossover study, where 50 individuals with type 2 diabetes will
change in a random order two regimens: six, and two meals a day. Each testing period will
take three months.
Glucose and lipid metabolism and its regulation will be thoroughly tested at start, and
after each 3-months-period (meal test, hyperinsulinemic isoglycemic clamp, indirect
calorimetry, MRI scan of the liver, DXA scan, serum concentration determination of selected
adipokines, gut hormones, and oxidation stress markers).
Hypothesis The investigators hypothesize that low plasma insulin levels (as achieved by
periods of fasting) will reduce insulin resistance and hepatic lipid content. In contrast,
frequent meals (and consequent higher plasma levels of insulin) will predispose to
non-alcoholic fatty liver disease and insulin resistance. The investigators further
hypothesize that the participants will increase their caloric intake with increased meal
frequency (in spite of thorough education) when left to prepare their meals in comparison
with those for whom all meals will be provided.
Key words Insulin resistance, meal frequency, type 2 diabetes mellitus, non-alcoholic fatty
liver disease, adipokines, gut hormones, oxidative stress Methodology Study design: the
investigators will use the design of a randomized, crossover study, where 50 individuals
with type 2 diabetes will change in a random order the frequency of their meals: six, and
two meals a day. Caloric restriction will be the same (-500 kcal/day). Each testing period
will take three months. For one half of the participants all meals during the study will be
provided. The other half will be thoroughly educated how to maintain their daily caloric
intake during both regimens and they will prepare their meals alone.
Study group: 50 individuals with type 2 diabetes treated by diet only or oral hypoglycemic
agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50
kg/m². The subjects will be explained aims, methods and risks of the study and they will
sign informed consent (Appendix 1).
Regimens: On the six-meals-per-day-regimen, participants will be asked to divide their total
caloric intake into six meals and to eat every two or three hours. On the
two-meals-per-day-regimen, they will divide their total caloric intake into two meals: the
first meal will be eaten between 6 and 10 a.m., the second one between noon and 4 p.m.
Physical activity: Participants will be asked not to change their exercise habits during the
study. Physical activity will be monitored using pedometers and standardized questionnaires:
International Physical Activity Questionnaire (IPAQ), and Baecke questionnaire.
Procedures:
At the beginning (week 0), and at the end of every 3 months (week 12, and 24), the following
procedures and measurements will be performed at each subject (three times in each subject):
1. Common anthropometric investigations (body weight, BMI, waist and hip circumference),
blood samples will be taken for laboratory assessments (common laboratory tests,
parameters of glucose and lipid metabolism, chosen adipokines, oxidative stress
markers, gut hormones, fatty acid composition in serum phospholipids etc.- see analytic
methods).
2. Meal test for glucose tolerance assessment after standard breakfast /baguette
Crocodille Cheese Gourmet - 180g, energy 452,8 Kcal/1895,7 kJ, composition:
carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of
which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g/. Blood samples for
the assessment of glycemia, C- peptide, immunoreactive insulin (IRI) will be taken in
0, 30, 60, 120 and 180 minutes after breakfast.
3. Hyperinsulinemic (1 mU/kg/min) isoglycemic clamp (HIC) 3 hours long with indirect
calorimetry. This method allows exact quantification of insulin resistance and energy
substrates utilisation.
4. MRI (magnetic resonance imaging) scan of the liver to measure the hepatic fat content.
5. DXA (Dual energy X-ray absorptiometry) scan to measure total body composition and fat
content.
6. Insulin secretion and glucose control will be measured during a one-day-stay in the
hospital at the end of each regimen. Blood samples will be taken every three hours
during the whole day. Urine will be collected during the whole day to measure
microalbuminuria and C-peptide waste.
Analytic methods:
Plasma concentrations of selected adipokines (resistin, adiponectin total, HMW- adiponectin,
TNFalfa and leptin) and other cytokines and proteins (FABP) will be measured enzymatically
using standard kits (ELISA, Linco, USA). Plasma levels of gut hormones will be measured
enzymatically usig standard kits (Milliplex, Millipore, USA). Parameters of lipid
peroxidation will be determined according to the levels of TBARS by the reaction with
thiobarbituric acid and according to the levels of conjugated dienes.
The level of reduced and oxidised glutathione will be determined using HPLC method with
fluorescence detection. Ascorbic acid will be determined spectrophotometric reaction with
dinitrophenylhydrazine. Concentrations of a- and g-tocopherol in serum will be determined by
reverse-phase high performance liquid chromatography (HPLC) with fluorescence detection
according to the modified method of Catignani and Biery. The activity of SOD will be
analyzed by the reaction of blocking nitrotethrazolium blue reduction and nitrophormasane
formation. Catalase activity measurement is based on the ability of H2O2 to produce with
ammonium molybdate the color complex detected spectrophotometrically. The activity of
gluthathione peroxidase will be monitored by oxidation velocity of gluthathione by Ellman
reagent. Serum glucose will be analysed using the glucose-oxidase method Beckman Analyzer
(Beckman Instruments Inc., Fullerton, CA, USA), IRI will be determined by radioimmunoassay
using an IMMUNOTECH Insulin IRMA kit (IMMUNOTECH as, Prague, Czech Republic), C-peptide
using an IMMUNOTECH C-Peptide IRMA kit (IMMUNOTECH as, Prague, Czech Republic) and glycated
hemoglobin will be measured by a Bio-Rad Haemoglobin A1c Column Test (Bio-Rad Laboratories
GmbH, Munich, Germany).
Fatty acid pattern in serum phospholipids will be measured after lipids extraction according
to Folch and separation of lipid fractions by thin-layer chromatography. The methylesters of
fatty acids will be separated by gas chromatography.
Eventual effects of different meal frequency regimens will be evaluated due to chosen gene
polymorphisms.
Statistic analysis: Will be done with the use of ANOVA tests, pair and unpair t- tests and
other statistic methods using standard statistic programs. Estimate of the number of
subjects to be recruited was done using power analysis of repeated measurements via
statistic software PASS 2005 (Number Cruncher Statistical Systems, Kaysville, UT, USA).
Factors included in this model are interindividual factors (control vs. experimental group),
intraindividual factors (individual time stadium in the study) and interaction between
factors (divergence degree between time profiles in control and experimental group).
Time frame: December 2010-February 2011 recruitment of the participants March 2011 start of
the study Group A: 12 weeks 6 meals/day followed by additional 12 weeks of 2 meal/day Group
B: 12 weeks 2 meals/day followed by additional 12 weeks of 6 meal/day September 2011 end of
the study
All measurements will be done at start, week 12 and week 24.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |